BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 8873383)

  • 1. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
    Stadler WM; Olopade OI
    Urol Res; 1996; 24(4):239-44. PubMed ID: 8873383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines.
    Zhou X; Suzuki H; Shimada Y; Imamura M; Yin J; Jiang HY; Tarmin L; Abraham JM; Meltzer SJ
    Genes Chromosomes Cancer; 1995 Aug; 13(4):285-90. PubMed ID: 7547637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies.
    Dreyling MH; Bohlander SK; Le Beau MM; Olopade OI
    Blood; 1995 Sep; 86(5):1931-8. PubMed ID: 7544647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines.
    Zhang H; Chen ZH; Savarese TM
    Cancer Genet Cytogenet; 1996 Jan; 86(1):22-8. PubMed ID: 8616780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
    Williamson MP; Elder PA; Shaw ME; Devlin J; Knowles MA
    Hum Mol Genet; 1995 Sep; 4(9):1569-77. PubMed ID: 8541841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
    Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
    Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.
    Packenham JP; Taylor JA; Anna CH; White CM; Devereux TR
    Mol Carcinog; 1995 Nov; 14(3):147-51. PubMed ID: 7576106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homozygous deletions at 9p21 in childhood acute lymphoblastic leukemia detected by microsatellite analysis.
    Takeuchi S; Koike M; Seriu T; Bartram CR; Slater J; Park S; Miyoshi I; Koeffler HP
    Leukemia; 1997 Oct; 11(10):1636-40. PubMed ID: 9324282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
    Schmid M; Malicki D; Nobori T; Rosenbach MD; Campbell K; Carson DA; Carrera CJ
    Oncogene; 1998 Nov; 17(20):2669-75. PubMed ID: 9840931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.
    Schmid M; Sen M; Rosenbach MD; Carrera CJ; Friedman H; Carson DA
    Oncogene; 2000 Nov; 19(50):5747-54. PubMed ID: 11126361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.
    Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H
    Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma.
    Elenitoba-Johnson KS; Gascoyne RD; Lim MS; Chhanabai M; Jaffe ES; Raffeld M
    Blood; 1998 Jun; 91(12):4677-85. PubMed ID: 9616165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas.
    Jagasia AA; Block JA; Qureshi A; Diaz MO; Nobori T; Gitelis S; Iyer AP
    Cancer Lett; 1996 Jul; 105(1):91-103. PubMed ID: 8689637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of the p16 and p15 genes in human bladder tumors.
    Orlow I; Lacombe L; Hannon GJ; Serrano M; Pellicer I; Dalbagni G; Reuter VE; Zhang ZF; Beach D; Cordon-Cardo C
    J Natl Cancer Inst; 1995 Oct; 87(20):1524-9. PubMed ID: 7563186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
    Balázs M; Carroll P; Kerschmann R; Sauter G; Waldman FM
    Genes Chromosomes Cancer; 1997 Jun; 19(2):84-9. PubMed ID: 9171998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines.
    Southgate J; Proffitt J; Roberts P; Smith B; Selby P
    Br J Cancer; 1995 Nov; 72(5):1214-8. PubMed ID: 7577470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma.
    Hamada K; Kohno T; Kawanishi M; Ohwada S; Yokota J
    Genes Chromosomes Cancer; 1998 Jul; 22(3):232-40. PubMed ID: 9624535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
    Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
    Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.
    García-Castellano JM; Villanueva A; Healey JH; Sowers R; Cordon-Cardo C; Huvos A; Bertino JR; Meyers P; Gorlick R
    Clin Cancer Res; 2002 Mar; 8(3):782-7. PubMed ID: 11895909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.